MGF

Plain-English version: MGF is a short-lived signal your muscle makes for itself. When a muscle is stretched, loaded, or damaged, it doesn't just read the "grow" instructions the normal way — it edits the IGF-1 gene's message on the fly to produce a special variant, and that variant is MGF. Think of it as the muscle's own "start repairs now" flare, fired in the first hours after a hard workout.

"MGF" stands for Mechano Growth Factor — "mechano" because it is switched on by mechanical stress. Formally it is a splice variant (an alternately edited version) of the IGF-1 gene, called IGF-1Ec in humans and IGF-1Eb in rodents. The stretch-induced IGF-1 isoform that would later be named MGF was first cloned from mechanically loaded skeletal muscle by Geoffrey Goldspink's group at University College London in 1996.^[1]

The IGF-1 gene has several exons (coding segments), and the cell can splice them together in different combinations. One combination makes the ordinary systemic IGF-1 (IGF-1Ea, the kind your liver pours into your blood). A different combination — favored when muscle is mechanically loaded — includes a short insert that shifts the reading frame and produces MGF's unique C-terminal "E domain." That E-domain peptide, roughly 24 amino acids, is the part found in no other IGF-1 variant, and it is the piece most synthetic "MGF" products are based on rather than the full-length IGF-1Ec protein.

Two versions circulate in the research-peptide market. Standard MGF mirrors the natural peptide and is extremely short-lived (a half-life measured in minutes), so it is injected directly into the trained muscle. PEG-MGF is the same peptide chemically attached to polyethylene glycol (PEG), a modification that shields it from rapid breakdown and stretches its half-life to hours — trading local specificity for a longer, more systemic action.

The credibility caveat, up front: a well-understood mechanism in cells is not proof in people. MGF is not approved as a drug in any country, has no NDA, BLA, or ANDA on file, is not a legitimate compounding-pharmacy substance, and is sold only "for research use only." It is also prohibited in sport by the World Anti-Doping Agency under class S2 (peptide hormones, growth factors, and related substances). For the wider legal picture, see Are Peptides Legal?

Takeaway first: MGF is best understood as the "activation" half of a two-part repair program. It wakes up and multiplies muscle stem cells, then hands off to mature IGF-1, which drives those cells to mature and fuse into fibers. That model is well-supported in cells and rodents. What is genuinely unsettled is which receptor MGF's E-domain acts through — and whether the effect reproduces reliably.

1. Satellite-cell activation (the core proposed mechanism)

Satellite cells are muscle-specific stem cells that sit dormant against the fiber until damage calls them into action. In rodent muscle, local tissue damage triggers the IGF-1 gene to splice toward MGF, and that spike is timed with the activation of satellite cells — the mechanistic basis for calling MGF a repair-initiation signal.^[3] Evidence level: rodent and ex vivo, not human.

2. A two-phase system: MGF proliferates, IGF-1 differentiates

In cultured muscle cells (C2C12 line), the MGF E-peptide and mature IGF-1 do different jobs: the MGF E-peptide pushes myoblasts (young muscle cells) to proliferate — multiply — while actually delaying their differentiation, whereas mature IGF-1 drives that differentiation and maturation.^[2] This split is the origin of the popular "MGF for activation, IGF-1 for differentiation" framing. The authoritative mechanism review that positions MGF as the mechanical-load-responsive local factor that "kick-starts" the adaptation is Goldspink's 2005 paper.^[4] Evidence level: cell culture and review.

3. Growth hormone feeds the MGF signal

The growth-hormone (GH) axis connects to local MGF production: in C2C12 muscle cells, growth hormone stimulated MGF expression and activated myoblast transformation.^[6] This helps explain why MGF is often discussed alongside GH secretagogues like ipamorelin and CJC-1295 — the pathways overlap. Evidence level: cell culture.

4. Neuroprotection through a different, uncharacterized receptor

One of the most intriguing findings is that MGF's action is not simply "IGF-1 receptor activation." The autonomous C-terminal MGF peptide strongly protected vulnerable neurons in a gerbil model of transient brain ischemia (interrupted blood flow), and this neuroprotection worked independently of the IGF-1 receptor.^[5] That points to a distinct, still-unidentified receptor for the E-domain peptide. Evidence level: animal (gerbil).

What we do NOT know

There is no confirmed human receptor for the MGF E-peptide, no established human pharmacokinetics (how injected MGF is absorbed, distributed, or cleared in people), and no human dose-response data. Critically, the mechanism is not even settled at the cell level: an independent industry lab reported that the MGF peptide had no apparent effect on myoblasts or primary muscle stem cells, failing to reproduce the proliferative/repair effect (covered in the Benefits section below).^[8] Treat the mechanism as a strong, well-argued hypothesis with a real replication problem, not a closed case.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Almost everything below is cell-culture or rodent work, and — unusually for a peptide — the single best human-cell result has a published failure to replicate. That is not a reason to dismiss MGF; it is a reason to keep expectations calibrated.

Satellite-cell activation and muscle repair

Claim: may kick-start muscle repair by activating satellite cells. Mechanism: local damage drives IGF-1-gene splicing to MGF, whose E-peptide recruits and multiplies satellite cells. Population: rodent muscle in vivo and ex vivo. Effect: MGF expression is timed with satellite-cell activation after local tissue damage, establishing it as the repair-initiation signal.^[3] Limitation: rodent/ex vivo only; this is the mechanism, not a demonstrated human recovery outcome. This satellite-cell angle is why MGF sits inside the muscle growth conversation.

Myoblast proliferation (the two-phase model)

Claim: may expand the pool of muscle-building cells before they mature. Mechanism: the MGF E-peptide favors proliferation and delays differentiation, complementary to mature IGF-1. Population: C2C12 muscle cell line in vitro. Effect: the MGF E-peptide increased myoblast proliferation while blocking premature differentiation, whereas mature IGF-1 did the opposite.^[2] Limitation: cell-culture only; effect sizes in a dish do not translate directly to human muscle.

Human muscle progenitor cells — the strongest human-cell signal

Claim: may work on human cells, even aged ones. Mechanism: activation of human satellite (muscle progenitor) cells and increased fusion potential (their ability to merge into fibers). Population: cultured human muscle progenitor cells from donors of different ages. Effect: the synthetic MGF E-peptide activated these human cells and increased their fusion potential, with the benefit preserved even in aged cells — suggesting exogenous MGF might compensate for the age-related decline in the body's own MGF.^[7] Limitation: human cells in a dish, not people; and see the replication problem directly below. (Note: older articles, including a previous version of this page, miscite this 2011 Kandalla study as "Ates et al. 2007" — it is the same work.)

The counter-evidence you must weigh: an independent replication failure

Claim being tested: that the MGF peptide reliably stimulates muscle cells. Population: human myoblasts and primary muscle stem cells. Result: an independent industry laboratory found the MGF peptide (the COOH-terminus of unprocessed IGF-1) had no apparent effect on myoblasts or primary muscle stem cells, failing to reproduce the proliferative and repair effects reported elsewhere.^[8] Why it matters: in YMYL health content this negative result is not a footnote — it means the central efficacy claim is genuinely contested at the cell level, before you even get to the missing human trials. A beginner should read this as: "even the lab evidence disagrees with itself."

Neuroprotection (beyond muscle)

Claim: may protect neurons after loss of blood flow. Mechanism: the C-terminal MGF peptide acting through a non-IGF-1-receptor pathway. Population: gerbils with transient brain ischemia. Effect: strong neuroprotection of vulnerable neurons, independent of the IGF-1 receptor.^[5] Limitation: a single animal model; do not extrapolate to human stroke or neurological disease.

The honest bottom line on "benefits"

• No completed human trials. There are no randomized controlled trials of exogenous MGF or PEG-MGF in humans, and no published human dosing, pharmacokinetic, or safety trial of injected MGF.
• The human-cell evidence is split. One lab found a clear effect on human progenitor cells; an independent lab found none. That is an unresolved contradiction, not settled science.
• In vivo efficacy is rodent-only. Every whole-animal result (muscle regeneration, brain-ischemia neuroprotection) comes from rodents or gerbils.
• Anecdotes are not data. Enthusiastic user reports cannot substitute for controlled trials, and product quality (see Sourcing) confounds them.

Read this first: there is no clinically validated human dose for MGF, because no human dosing trial of injected MGF or PEG-MGF has ever been completed or published. The figures below circulate in the research-peptide community and are extrapolated from mechanism and animal work, not derived from human trials. We describe them for completeness and harm reduction, not as medical guidance or an endorsement of self-administration.

Commonly cited research protocols (extrapolated, not validated)

Form	Commonly cited dose	Frequency	Route	Rationale
Standard MGF	200-400 mcg	Immediately post-workout	Intramuscular, into the trained muscle (often split bilaterally)	Minutes-long half-life demands local, immediate delivery
PEG-MGF	200-400 mcg	2-3x per week	Subcutaneous or intramuscular	Hours-long half-life allows less frequent, more systemic dosing

Route logic in plain terms

Standard MGF is so short-lived (a half-life of minutes) that a subcutaneous shot into a fat pad would largely be degraded before reaching target tissue — which is why the community protocol injects it intramuscularly, into the muscle you just trained, right after training, sometimes split across two sites to spread it through the tissue. That mirrors MGF's natural biology: a brief, local flare at the damage site. PEG-MGF, protected by its PEG chain, survives long enough to be injected subcutaneously and act more broadly, at the cost of the site-specific precision standard MGF is prized for.

Reconstitution math, with a worked example

MGF ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mcg/mL) = vial amount (mcg) ÷ water added (mL)

Worked example: take a 2 mg (2,000 mcg) vial and add 1 mL of bacteriostatic water. That gives 2,000 ÷ 1 = 2,000 mcg/mL. To draw a 200 mcg dose: 200 ÷ 2,000 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe. A 400 mcg dose is 0.20 mL, or 20 units.

Vial	BAC water	Concentration	200 mcg	400 mcg
2 mg	1 mL	2,000 mcg/mL	0.10 mL (10 units)	0.20 mL (20 units)
2 mg	2 mL	1,000 mcg/mL	0.20 mL (20 units)	0.40 mL (40 units)
5 mg	2 mL	2,500 mcg/mL	0.08 mL (8 units)	0.16 mL (16 units)

Preparation: wipe the stopper with alcohol, inject the water slowly down the vial wall rather than onto the powder, swirl gently (never shake), and label with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Cycle length, timing, and storage

• Timing (standard MGF): the minutes-long half-life makes timing the whole game — it must go in immediately post-workout into the trained muscle, not hours later.
• Timing (PEG-MGF): less time-critical; commonly dosed on training days or 2-3x weekly.
• Cycle length: community protocols commonly run 4-6 weeks. This is convention, not a trial-derived duration.
• Storage: keep lyophilized vials frozen (around -20°C) for long-term stability. Once reconstituted, refrigerate at 2-8°C; standard MGF is extremely unstable in solution and is best used immediately, while PEG-MGF is more stable and is typically used within about 2-3 weeks. Do not re-freeze a reconstituted solution.

None of the above is a recommendation to self-administer an unapproved compound. It is a description of how the research doses are structured.

Straight talk: essentially no human clinical safety data exists for injected MGF or PEG-MGF. No formal human safety trial has been published, so the profile below is assembled from the IGF-1 class's known risks, rodent and cell studies, and uncontrolled community reports. That is reassurance built on inference, not a clean safety record — the absence of documented serious harm mostly reflects the absence of any formal study, not proof of safety.

Reported side effects (mostly community experience, not trials)

Effect	Frequency / source	Notes
Injection-site pain or soreness	Common (anecdotal)	IM injection into an already-sore trained muscle is more uncomfortable than an abdominal SC shot
Local swelling or "pump" sensation	Common (anecdotal)	Expected with local IGF-1-family activity
Mild hypoglycemia / lightheadedness	Uncommon	IGF-1-pathway crosstalk with insulin; more likely with systemic PEG-MGF than local standard MGF
Headache	Reported anecdotally	Usually transient
Injection-site lump / lipohypertrophy	Possible with poor site rotation	Local growth-factor activity; rotate sites
Allergic reaction	Rare	Discontinue immediately and seek care

No serious adverse events have been formally documented — because no formal human safety study has been done. Read that as a data gap, not a green light.

IGF-1 class theoretical concerns

MGF sits in the IGF-1 family, so the class's theoretical risks apply, with one important qualifier: standard MGF's local, minutes-long action is expected to cause far less sustained systemic IGF-1 signaling than direct IGF-1 LR3, while PEG-MGF's longer, more systemic exposure is less well characterized and carries more of these concerns.

• Cancer risk (theoretical): a systematic review and meta-regression found that high circulating IGF-1 is associated with increased risk of prostate and premenopausal breast cancer.^[9] That study does not test MGF directly, but because MGF activates IGF-1-pathway biology it is the relevant class-level caution. Anyone with active or recent cancer should avoid MGF.
• Glucose dysregulation: IGF-1-family signaling crosses over with insulin signaling and can lower blood glucose — more of a concern with systemic PEG-MGF and in anyone on glucose-lowering medication.
• Acromegaly-pattern effects with chronic high-dose use: joint pain and soft-tissue thickening are theoretically plausible from sustained IGF-1-pathway activation, though not documented at typical research doses.

Standard MGF vs PEG-MGF: different risk profiles

• Standard MGF — minutes-long half-life, acts at the injection site with minimal systemic exposure. Theoretically the lower-risk of the two, but its effects are mostly local.
• PEG-MGF — hours-long half-life and broader systemic distribution, so more of the IGF-1-class concerns above apply. Neither form has formal human safety data.

Who should avoid MGF

• Active or recent cancer: IGF-1-pathway activation is theoretically mitogenic — avoid.
• Personal or family history of breast, prostate, or colorectal cancer: relative contraindication; discuss with a clinician.
• Active diabetic retinopathy: IGF-1-family activity can worsen proliferative retinopathy — avoid.
• Uncontrolled diabetes: monitor glucose closely if used at all.
• Pregnancy and breastfeeding: no data — avoid.
• Combining with insulin, sulfonylureas, GH secretagogues, or exogenous IGF-1: additive/redundant IGF-1-pathway or glucose-lowering effects; not well studied.

What to do if you experience side effects

• Injection-site soreness: rotate sites; it usually resolves within 24-48 hours.
• Hypoglycemic symptoms (sweating, shakiness, hunger): take fast-acting carbohydrate, reduce dose, and if it recurs discontinue and check fasting glucose.
• A new or changing skin lesion, mole, or nodule: get it evaluated — IGF-1-pathway activity warrants attention to anything growing.
• Allergic reaction: stop immediately and seek emergency care.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this matters: MGF is an unregulated research compound, and there is a specific technical wrinkle that raises the stakes — the peptides sold as "MGF" and "PEG-MGF" are not simple, well-characterized molecules, and identity and purity vary widely between suppliers. For an unproven compound whose benefit is already contested in the lab, an impure or mislabeled vial is arguably a bigger practical hazard than the peptide itself. Learning to read a Certificate of Analysis (COA) is the most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight for the specific product (standard MGF vs PEG-MGF differ).
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial — not a pre-mixed liquid.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed "ready to use" liquid MGF — especially problematic given standard MGF's instability in solution
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any indication, in any country. There is no approved MGF or PEG-MGF drug product, and no NDA, BLA, or ANDA on file.
• Not a legitimate compounding item and sold only "for research use only."
• Banned in sport: WADA prohibits MGF under class S2 (peptide hormones, growth factors, and related substances), so competitive athletes should treat it as bannable.
• Not a controlled substance: MGF is not DEA-scheduled.

For the complete legal picture, read Are Peptides Legal? and see the peptide storage guide for handling.

MGF and IGF-1 LR3 both come from the IGF-1 system but do different jobs, which is why they are sometimes discussed as a pair rather than as alternatives. None of the comparisons below are backed by head-to-head human trials — they contrast proposed mechanisms and the preclinical literature.

Feature	MGF	IGF-1 LR3
Origin	Splice variant of the IGF-1 gene (C-terminal E domain)	Engineered long-acting analog of mature IGF-1
Proposed role	Satellite-cell activation / repair initiation	Sustained systemic anabolism (protein synthesis)
Action range	Local (autocrine/paracrine)	Systemic
Half-life	Minutes (standard MGF); hours (PEG-MGF)	Roughly 20-30 hours
Receptor	E-peptide target not fully characterized; some actions independent of IGF-1R[5]	IGF-1 receptor (IGF-1R)
Temporal role	Immediate post-damage (hours)	Sustained (days)

Some protocols alternate MGF (post-workout, for satellite-cell activation) with IGF-1 LR3 (for sustained anabolism) to try to mimic the natural two-phase repair cascade. Be clear-eyed about this: it is extrapolation from mechanism, not a human-validated protocol, and it stacks two IGF-1-pathway compounds — increasing the class-level theoretical risks in the Safety section. It is also worth remembering that MGF's own core efficacy is contested even at the cell level.^[8]